Key takeaways from the Fall 2025 AARR meeting are presented, which brought together academic, clinical, and industry leaders to discuss and explore the current advances in the heterogeneity and co‐pathologies of AD and their implications for diagnosis, clinical trial design, and precision treatment strategies.
Abstract
Abstract Alzheimer's disease (AD) is a biologically heterogeneous condition with vascular, proteinopathic, metabolic, and immune processes jointly shaping its clinical expression, trajectory of progression, and response to therapeutic intervention. Common AD co‐pathologies such as cerebral amyloid angiopathy, Lewy body pathology, α‐synuclein, and transactive response DNA‐binding protein of 43 kDa (TDP‐43)/limbic‐predominant age‐related TDP‐43 encephalopathy are also increasingly connected with cognitive decline and therapeutic response. Significant advances in biomarkers, including seed amplification assays, proteomic signatures, and emerging positron emission tomography tracers bolster the field's understanding of a biological staging model and discovery of previously unrecognized co‐pathologies. The Fall 2025 Alzheimer's Association Research Roundtable (AARR) brought together academic, clinical, and industry leaders to discuss and explore the current advances in the heterogeneity and co‐pathologies of AD, and their implications for diagnosis, clinical trial design, and precision treatment strategies. This paper presents key takeaways from the Fall 2025 AARR meeting.
This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.
Priya, Radhika Mittal, Jyotirmoy Banerjee et al.· International review of neur...· 0 citations
This narrative review examines AD mechanisms, biomarkers, and therapeutic prospects from a geroscience perspective and applies the eight hallmarks of neurodegenerative diseases as an analytical framework to establish which preventive strategies and biomarker-guided, stage-matched combination therapies improve clinicall...
Evidence supports a shift from a linear amyloid model to a multidimensional framework and offers promise for early detection, risk stratification, and personalized multi-target therapies in AD.
C. D. Souza, Shiva Murthy Nanjundappa, N. Murali· International Journal of Bas...· 0 citations
A combination of biomarker-guided diagnostics with mechanism-based therapies might enable precision medicine approaches and improve clinical outcomes in AD.
There is a critical need for future AD research to bridge identified gaps in early detection, focus on improving early diagnosis, developing more effective treatments, refining existing drugs and therapies, and understanding the underlying disease progression mechanisms.
S. Patnaik, P. K. Patra, Chinam Niranjan Patra et al.· Central Nervous System Agent...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.